Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) traded at $1.41 at last check on Tuesday, Jun 30, making a downturn move of -2.76% on its previous day’s price.

Looking at the stock we see that its previous close was $1.45 and the beta (5Y monthly) reads 1.21 with the day’s price range being $1.3500 – 1.5500. In terms of its 52-week price range, CTXR has a high of $1.97 and a low of $0.4. The company’s stock has gained about 67.05% over that past 30 days.

On the other hand, looking at the outlook for the CTXR stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 100% Buy. Long term indicators on average place the stock in the category of 100% Buy.

Based on estimates by 2 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the Citius Pharmaceuticals, Inc. (CTXR) stock as a Hold, while 2 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.

Looking further, we note that the PEG ratio for the CTXR stock currently stands at 0, and the current price level is 45.72% off its SMA20 and 54.73% from its 50-day simple moving average. The RSI (14) is pointing at 76.37 while the volatility over the past week is 26.42% and drops to 12.48% over the past one month. The beta value is 1.76, while the average true range (ATR) is currently pointing at 0.15. The average price target for the stock over the next 12 months is $5.5, with the estimates having a low of $4 and a high of $7. These price ends are 183.69% and +396.45% off the current price level respectively, although investors could be excited at the prospect of a +290.07% if the CTXR share price touches on the median price of $5.5.

Let’s briefly compare Citius (CTXR) stock to its peers. We find that today’s price change of -2.76% and +47.96% over the past 12 months for CTXR competes that of Zoetis Inc Cl A (ZTS), which has seen its stock price rise 2% in the latest trading session and is +16.29% over the last one year. Another of its peers Takeda Pharmaceutical Co. Ltd (TAK) has dropped -1.91% today, and is +2.32% up over the past year, while Grifols S.A. (GRFS) is also down -2.76% yet its price remains in the green at 47.96% over the same period. Zoetis has a P/E ratio of 39.26 compared to Citius’ 0 and Takeda’s 22.32. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.04% and 0.46%, respectively, in early deals.

Coming back to Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), we note that the average 3-month trading volume was 2.83 Million, while that of the preceding 10-day period stands at 14.67 Million. Current shares outstanding are 45.19 Million.

According to data from Thomson Reuters, insiders hold 39.08% of the company’s shares while institutions hold 12.53%. The data shows that short shares as of June 14, 2020, stood at 952.3 Million at a short ratio of 0.45. This represents a 2.11% Short interest in Shares outstanding on June 14, 2020. Shares short rose in June from the previous month at 1.3 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock +42.16% up in year-to-date price movement.